Abraham, Fruchter, & Twersky LLP

Abraham, & Fruchter, Twersky, LLP

Isis Pharmaceuticals, Inc.

Lead Plaintiff Deadline: 02/26/13

Date filed: 12/28/12

Class period: March 29, 2012 through October 15, 2012

Court: Southern District of California

NASDAQ: ISIS

Abraham, Fruchter & Twersky, LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities that purchased the stock of Isis Pharmaceuticals, Inc. (“Isis Pharmaceuticals” or the “Company”) (NASDAQ: ISIS) from March 29, 2012 through October 15, 2012, inclusive (the “Class Period”), alleging violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and certain of its officers (the “Complaint”).

Isis Pharmaceuticals, based in Carlsbad, California, is the leading company in gene-blocking antisense drug discovery and development. The Company’s flagship product, Kynamro (formerly mipomersen), is designed to treat patients with severe forms of high cholesterol. The Complaint alleges that throughout the Class Period, Isis Pharmaceuticals issued false and misleading statements regarding the safety and efficacy of the drug, as well as reportedly positive results from Kynamro’s phase three clinical trial, leading investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration (“FDA”).

On October 16, 2012, an FDA advisory committee posted information on the FDA’s website noting that in recent patient studies, 3.1 percent of patients, or 23 people treated with Kynamro developed tumors and three of them died, while only 0.9 percent, or two patients getting a placebo developed tumors.  The Endocrinologic and Metabolic Drugs Advisory Committee also noted liver and blood vessel cancers were seen in earlier tests of the drug conducted on mice.

As a result of this disclosure, the price per share of Isis Pharmaceuticals common stock declined $2.88, or nearly 22%, to close that day at $10.27, on heavy trading volume.

Contact Us

If you purchased Isis Pharmaceuticals common stock from March 29, 2012 through October 15, 2012, inclusive, and you would like to discuss these claims or if you have any questions concerning this notice or your rights as a potential class member or lead plaintiff, please contact an AF&T attorney.  If you would like information on how to participate in this action, please fill out the form below.